Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $16.66 USD
Change Today -0.36 / -2.12%
Volume 92.1K
OSIR On Other Exchanges
As of 8:10 PM 10/8/15 All times are local (Market data is delayed by at least 15 minutes).

osiris therapeutics inc (OSIR) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/17/15 - $23.67
52 Week Low
10/9/14 - $11.98
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

osiris therapeutics inc (OSIR) Related Businessweek News

No Related Businessweek News Found

osiris therapeutics inc (OSIR) Details

Osiris Therapeutics, Inc. researches, develops, manufactures, markets, and distributes regenerative medicine products in the United States. Its products include Grafix, a cryopreserved placental membrane for treating hard-to-treat acute and chronic wounds, venous leg ulcers, and burns; BIO4, a bone allograft for use in all surgical applications, including spine, trauma, extremity, cranial, and foot and ankle surgery; and Cartiform, a viable chondral allograft that promotes articular cartilage repair to treat focal chondral defects. It markets and distributes its products directly to hospitals, clinics, and physician offices as well as through agents and distributors. Osiris Therapeutics, Inc. was founded in 1992 and is headquartered in Columbia, Maryland.

211 Employees
Last Reported Date: 03/20/15
Founded in 1992

osiris therapeutics inc (OSIR) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $510.0K
Chief Financial Officer
Total Annual Compensation: $27.6K
Chief Medical Officer
Total Annual Compensation: $28.6K
Vice President and General Manager of Wound C...
Total Annual Compensation: $328.2K
Compensation as of Fiscal Year 2014.

osiris therapeutics inc (OSIR) Key Developments

Osiris Announces Initiation of A Phase III Trial for a New Investigational Drug, OTI-15-01, for the Treatment of Chronic Diabetic Foot Wounds

Osiris Therapeutics, Inc. announced the initiation of its Multicenter, Randomized, Blinded Study with an Open-Label Extension Option to Evaluate the Safety and Efficacy of OTI-15-01 for the Treatment of Chronic Diabetic Foot Ulcers. The phase III trial is designed as a randomized, controlled, blinded study, and is expected to enroll up to 224 patients in approximately 20 sites. Patients will be randomized to receive OTI-15-01 plus standard of care versus standard of care alone, which includes debridement, a non-adherent dressing, and standardized off-loading. The primary endpoint is the proportion of patients with complete wound healing by week 12, with confirmation of durability of complete wound healing during two subsequent visits two weeks apart. Secondary endpoints include time to healing, week 4 wound size reduction, number of applications and overall safety, including wound specific adverse events. Patients in the control arm who receive standard of care and do not heal within 12 weeks will be able to receive active drug in an open-label crossover arm of the trial for up to 12 additional weeks. The study design was reviewed by the FDA and meets the requirements established by FDA in the 2006 guideline for Industry clinical trials for products used to treat burns and cutaneous ulcers. This protocol for OTI-15-01 is conducted under the Investigational New Drug (IND) application IND 16383.

Osiris Therapeutics, Inc. Presents at Alliance for Regenerative Medicine Stem Cell Meeting on the Mesa, Oct-08-2015 02:30 PM

Osiris Therapeutics, Inc. Presents at Alliance for Regenerative Medicine Stem Cell Meeting on the Mesa, Oct-08-2015 02:30 PM. Venue: Estancia La Jolla Hotel & Spa, 9700 North Torrey Pines Road, La Jolla, CA 92037, United States. Speakers: Lode Debrabandere, Chief Executive Officer, President and Director.

Osiris Therapeutics Declares Special Cash Dividend, Payable on October 30, 2015

Osiris Therapeutics, Inc. announced that its Board of Directors declared a cash dividend of $0.20 per share of common stock, payable on October 30, 2015 to stockholders of record as of October 16, 2015.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OSIR:US $16.66 USD -0.36

OSIR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioTime Inc $3.50 USD +0.16
CryoLife Inc $10.35 USD +0.13
Derma Sciences Inc $5.10 USD -0.01
Vericel Corp $2.44 USD +0.02
Vitrolife AB kr180.00 SEK -1.00
View Industry Companies

Industry Analysis


Industry Average

Valuation OSIR Industry Range
Price/Earnings 100.0x
Price/Sales 7.4x
Price/Book 6.8x
Price/Cash Flow 151.3x
TEV/Sales 6.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OSIRIS THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at